Chronic infection with the hepatitis C virus (HCV) is a major cause of cirrhosis, decompensated liver disease and hepatocellular carcinoma (HCC) worldwide. Globally there are an estimated 180 million persons with HCV. In the United States (U.S.), there are 4.1 million persons who are anti-HCV positive, 3.2 million of whom have chronic infection based on the detection of HCV RNA in serum. In 2011, chronic liver disease was the 10th leading cause of death in the U.S. most due to chronic HCV infection. These figures underscore the magnitude and impact that chronic HCV infection has on global and US public health. The natural history of chronic HCV infection has been difficult to study. The protracted and silent course of infection, the absence of large cohorts of persons known to be infected, and the wide variability in outcome are major obstacles to natural history studies. Five to twenty-five percent of HCV-infected persons will develop cirrhosis over a 25-30 year period but some patients remain asymptomatic, without significant liver disease for many decades if not for life. Knowledge of the rate of progression among individuals who have not developed cirrhosis is unknown. An equally important and related issue is the clinical assessment of disease severity. Unfortunately, there are no good laboratory markers of disease severity and liver biopsy, the accepted gold standard for assessing disease severity is imperfect. Non-invasive methods to assess disease severity are highly desirable for the clinicians diagnostic toolbox. The optimal treatment for chronic HCV infection is undergoing a paradigm change with the advent of direct acting antiviral (DAA) agents. For genotype 1 infection response rates now approach 70-75%, close to that of genotypes 2 and 3. The challenging group of patients to treat are those who have failed a prior course of peginterferon and ribavirin and those with advanced disease. Therapeutic options for these subjects are improving but few studies have been conducted in these patient populations. Thus studies using newer, safer and more effective therapies are urgently needed for these sub-populations with chronic HCV infection. Hypotheses/problems addressed: 1) Define the host, viral and environmental factors that determine the natural history and outcome of HCV infection. To address this problem, we have created a large database of untreated patients with chronic HCV (n700) and have analyzed this database to identify factors that affect the natural history of chronic HCV infection. We have published 3 studies on this cohort, identifying clinical factors and candidate genes associated with fibrosis progression. To further define factors associated with fibrosis progression and clinical outcome of chronic hepatitis C, we prospectively monitored a large, well characterized cohort of over 1000 patients who participated in a randomized, controlled, multi-center trial of long-term peginterferon versus no therapy for patients with advanced HCV infection (HALT-C-see below) for 8 years. Important data describing the natural history of advanced chronic hepatitis C has been derived from this study. We have demonstrated that increase in weight and weight-related conditions such as diabetes and insulin resistance were associated with a greater likelihood of fibrosis progression or experiencing a clinical outcome (development of ascites, spontaneous bacterial peritonitis, hepatic encephalopathy and variceal hemorrhage) in patients with advanced chronic hepatitis C. In contrast, regular coffee consumption was shown to be associated with a lower rate of liver disease progression. Importantly, we showed for the first time that the Ishak scoring system used to stage fibrosis, predicted clinical outcomes, need for liver transplantation, and liver-related death in patients with chronic hepatitis C. Taken together these results would allow physicians to more accurately counsel patients with hepatitis C on their risk of an adverse outcome and to provide simple, straight-forward, evidence-based lifestyle changes that may decrease their risk for disease progression. We have also combined patients from the NIH and HALT-C cohorts to examine the role of IL-28b polymorphisms on fibrosis progression and clinical outcomes. Our data suggests no association of IL28b with fibrosis progression but we did observe a higher rate of clinical outcomes in patients with IL28b CC genotype. Finally, we are validating the usefulness of a new technology, ultrasound elastography, to non-invasively assess hepatic fibrosis. Results revealed that the device has a 96% accuracy for prediction of cirrhosis. Studies are ongoing to compare Fibroscan and MRI elastography to liver biopsy, and plasma will be stored for future proteomic analysis. Our goal is to develop a series of blood and imaging test that will obviate the need for liver biopsy in most patients with chronic HCV infection. 2) Develop and evaluate novel, safer and more effective therapies for chronic viral hepatitis. Management options for non-responders to peginterferon and ribavirin are limited. Ribavirin, a guanosine nucleoside analogue is critically important for the success of therapy for CHC. Several post-hoc analyses and one pilot study have suggested that higher doses of ribavirin may be associated with higher rates of viral clearance. Accordingly, we have conducted an open label study to evaluate the safety and efficacy of high dose ribavirin in combination with standard dose peginterferon alfa-2a for non-responder and relapser patients with CHC. The results showed that 48% (10/21) patients achieved an end-of-treatment response and 15% (3/20) have successfully achieved long-term clearance of the virus. We have recently initiated a trial evaluating two new agents asunaprevir and daclatasvir either together or in combination with peginterferon and ribavirin to treat prior non-responders to peginterferon and ribavirin. 3. Elucidate the viral pathogenesis of chronic HCV infection and mechanisms of action of anti-viral therapy The conduct of clinical trials over the last 30 years has allowed the LDB to acquire invaluable clinical material (patient serum, liver tissue and lymphophocytes) to which state of the art laboratory techniques can be applied to address issues of the pathogenesis of HCV infection and the mechanisms of action of antiviral therapy. In association with the above clinical study using asunaprevir and daclatasvir we plan to study changes in interferon stimulated genes (ISGs) before and during therapy to answer two critical questions: (1) whether ISGs which are maximally upregulated in interferon non-responders can return to baseline levels and (2) whether interferon responsiveness can be restored in non-responders after suppressing viral replication with potent direct antiviral agents.

Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2013
Total Cost
$364,255
Indirect Cost
City
State
Country
Zip Code
Noureddin, Mazen; Wright, Elizabeth C; Ghany, Marc G (2014) Reply: To PMID 23703931. Hepatology 59:1651
Liang, T Jake; Ghany, Marc G (2014) Therapy of hepatitis C--back to the future. N Engl J Med 370:2043-7
Ghany, Marc G; Gara, Naveen (2014) QUEST for a cure for hepatitis C virus: the end is in sight. Lancet 384:381-3
Noureddin, Mazen; Wright, Elizabeth C; Alter, Harvey J et al. (2013) Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 58:1548-57
Samala, Niharika R; Ghany, Marc G (2013) Acute hepatitis C: to treat or not to treat. Lancet Infect Dis 13:467-8
Henderson, Wendy A; Shankar, Ravi; Gill, Jessica M et al. (2010) Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat 17:59-64
Ghany, Marc G; Strader, Doris B; Thomas, David L et al. (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335-74
Kottilil, Shyam; Yan, Michael Y; Reitano, Kristin N et al. (2009) Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology 50:34-45